| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.IJPHARM.2015.05.023 |
| P698 | PubMed publication ID | 25980731 |
| P50 | author | Barbara McKenzie | Q56356255 |
| Graeme Kay | Q56356262 | ||
| Donald Cairns | Q56356271 | ||
| Rachel M Knott | Q56356278 | ||
| Kerr H Matthews | Q56356287 | ||
| P2860 | cites work | Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops | Q30927446 |
| Ophthalmic manifestations and histopathology of infantile nephropathic cystinosis: report of a case and review of the literature | Q35748378 | ||
| Successful use of topical cysteamine formulated from the oral preparation in a child with keratopathy secondary to cystinosis | Q35920359 | ||
| Pharmacological treatment of nephropathic cystinosis with cysteamine | Q35925508 | ||
| Clot volume and clearance rate as independent predictors of vasospasm after aneurysmal subarachnoid hemorrhage | Q39692079 | ||
| Ophthalmic drug delivery systems | Q40224103 | ||
| Minimizing systemic absorption of topically administered ophthalmic drugs | Q40710654 | ||
| Ophthalmic drug delivery systems--recent advances | Q41736662 | ||
| Digitally quantifying cerebral hemorrhage using Photoshop and Image J. | Q42737172 | ||
| Validation study of alternatives to the Draize eye irritation test in Germany: Cytotoxicity testing and HET-CAM test with 136 industrial chemicals | Q42808245 | ||
| Gel formulations for treatment of the ophthalmic complications in cystinosis | Q43103869 | ||
| Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery | Q43254741 | ||
| Evolution of ocular manifestations in nephropathic cystinosis: a long-term study of a population treated with cysteamine. | Q44470986 | ||
| Treatment of cystinosis: simple in principle, difficult in practice | Q45103561 | ||
| Effect of polymer viscosity on physicochemical properties and ocular tolerance of FB-loaded PLGA nanospheres. | Q46031769 | ||
| The pH of multi-purpose soft contact lens solutions. | Q46063722 | ||
| A potential new prodrug for the treatment of cystinosis: design, synthesis and in-vitro evaluation. | Q46771965 | ||
| Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system | Q46890444 | ||
| W/O microemulsions for ocular delivery: evaluation of ocular irritation and precorneal retention. | Q46903954 | ||
| Physical properties of soft contact lens solutions | Q47892488 | ||
| White matter injury in young and aged rats after intracerebral hemorrhage | Q48883988 | ||
| Interlaboratory validation of in vitro eye irritation tests for cosmetic ingredients. (2) Chorioallantoic membrane (CAM) test | Q50520391 | ||
| The origin of halitosis in cystinotic patients due to cysteamine treatment. | Q54054715 | ||
| Ocular changes in long-term evolution of infantile cystinosis | Q59619443 | ||
| Detection and characterization of a transport system mediating cysteamine entry into human fibroblast lysosomes. Specificity for aminoethylthiol and aminoethylsulfide derivatives | Q72465681 | ||
| A randomized clinical trial of topical cysteamine disulfide (cystamine) versus free thiol (cysteamine) in the treatment of corneal cystine crystals in cystinosis | Q77364441 | ||
| Evaluation of a modified HET-CAM assay as a screening test for eye irritancy | Q84585638 | ||
| Evaluation of the HET-CAM-TSA method as an alternative to the draize eye irritation test | Q84589413 | ||
| In situ forming collagen-hyaluronic acid membrane structures: mechanism of self-assembly and applications in regenerative medicine | Q87395882 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 1-2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ImageJ | Q1659584 |
| P6104 | maintained by WikiProject | WikiProject Software | Q15659621 |
| P304 | page(s) | 1-8 | |
| P577 | publication date | 2015-07-25 | |
| P1433 | published in | International Journal of Pharmaceutics | Q6051539 |
| P1476 | title | The hen's egg chorioallantoic membrane (HET-CAM) test to predict the ophthalmic irritation potential of a cysteamine-containing gel: Quantification using Photoshop® and ImageJ | |
| P478 | volume | 490 |
| Q101410601 | Acute, reproductive, and developmental toxicity of essential oils assessed with alternative in vitro and in vivo systems |
| Q95645064 | Analytical tools and evaluation strategies for nanostructured lipid carrier based topical delivery systems |
| Q92122418 | Characterization of Ginkgo biloba Leaf Flavonoids as Neuroexocytosis Regulators |
| Q57291071 | Chitosan-Based In Situ Gels for Ocular Delivery of Therapeutics: A State-of-the-Art Review |
| Q94571979 | Chitosan-Coated Lipid-Core Nanocapsules Functionalized with Gold-III and Bevacizumab Induced In Vitro Cytotoxicity against C6 Cell Line and In Vivo Potent Antiangiogenic Activity |
| Q91649538 | Combination of microneedles and microemulsions to increase celecoxib topical delivery for potential application in chemoprevention of breast cancer |
| Q89997060 | Cow ghee fortified ocular topical microemulsion; in vitro, ex vivo, and in vivo evaluation |
| Q64943766 | Cyclodextrin⁻Amphiphilic Copolymer Supramolecular Assemblies for the Ocular Delivery of Natamycin. |
| Q50574842 | Cysteamine polysaccharide hydrogels: Study of extended ocular delivery and biopermanence time by PET imaging. |
| Q90224891 | Development, Cytotoxicity and Eye Irritation Profile of a New Sunscreen Formulation Based on Benzophenone-3-poly(ε-caprolactone) Nanocapsules |
| Q90166036 | Development, Skin Targeting And Antifungal Efficacy Of Topical Lipid Nanoparticles Containing Itraconazole |
| Q100311619 | Effect of nanoemulsion modification with chitosan and sodium alginate on the topical delivery and efficacy of the cytotoxic agent piplartine in 2D and 3D skin cancer models |
| Q53760733 | Effect of pH and penetration enhancers on cysteamine stability and trans-corneal transport. |
| Q111348938 | Enhanced protective potential of novel citronella essential oil microsponge hydrogel against Anopheles stephensi mosquito |
| Q91867116 | In Vitro and Ex Vivo Evaluation of Nepafenac-Based Cyclodextrin Microparticles for Treatment of Eye Inflammation |
| Q99203400 | In vitro and in vivo amelioration of colitis using targeted delivery system of cyclosporine A in NewZealand rabbits |
| Q39054651 | In vitro and in vivo evaluation of in situ gelling systems for sustained topical ophthalmic delivery: state of the art and beyond. |
| Q91662734 | Innovative strategy based on mechanisms to substitute animal testing for ocular toxicity assessment of agrochemical formulations market in Brazil |
| Q47962328 | Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma |
| Q50421324 | Multifunctional nanoemulsions for intraductal delivery as a new platform for local treatment of breast cancer |
| Q92296603 | Nano-hydroxyapatite in oral care cosmetics: characterization and cytotoxicity assessment |
| Q93077116 | Optimization of composition and obtainment parameters of biocompatible nanoemulsions intended for intraductal administration of piplartine (piperlongumine) and mammary tissue targeting |
| Q47872268 | PEGylated PLGA nanospheres optimized by design of experiments for ocular administration of dexibuprofen-in vitro, ex vivo and in vivo characterization. |
| Q40822954 | Poloxamer-hydroxyethyl cellulose-α-cyclodextrin supramolecular gels for sustained release of griseofulvin |
| Q90772464 | Polypseudorotaxanes of Pluronic® F127 with Combinations of α- and β-Cyclodextrins for Topical Formulation of Acyclovir |
| Q98205081 | Reduction of focal sweating by lipid nanoparticle-delivered myricetin |
| Q92137003 | Repositioning of Itraconazole for the Management of Ocular Neovascularization Through Surface-Modified Nanostructured Lipid Carriers |
| Q96122149 | Skin irritation potential of cosmetic preservatives: An exposure-relevant study |
| Q93056256 | Slow degrading hyaluronic acid hydrogel reinforced with cationized graphene nanosheets |
| Q64955686 | Solid Lipid Nanoparticle: An Efficient Carrier for Improved Ocular Permeation of Voriconazole. |
| Q100697650 | Therapeutic nanoemulsions in ophthalmic drug administration: Concept in formulations and characterization techniques for ocular drug delivery |
| Q91564762 | Unveiling the potentials of bacteriocin (Pediocin L50) from Pediococcus acidilactici with antagonist spectrum in a Caenorhabditis elegans model |
| Q89274818 | α-Lipoic Acid in Soluplus(®) Polymeric Nanomicelles for Ocular Treatment of Diabetes-Associated Corneal Diseases |
Search more.